TRAF6 and neoplasm: For miR-146a, NF-κB dampening through IRAK1/TRAF6 targeting can reduce inflammatory cytokines and support anti-tumor immunity, yet in specific inflammatory milieus negative-feedback regulation may also favor tumor persistence by blunting acute immune activation [25,26].